ا.د / نهى نبيل سلامه محمد احمد سلامه
الصيدلانيات و الصيدلة الصناعية
noha.salama@pharma.cu.edu.eg
Latest List of Publications
1- Telavancin pharmacokinetics in patients with chronic kidney disease receiving haemodialysis.
Gharibian KN, Lewis SJ, Heung M, Segal JH, Salama NN, Mueller BA.
J Antimicrob Chemother. 2021 Dec 24;77(1):174-180. doi: 10.1093/jac/dkab370.
PMID: 34613416
2- Targeting E-selectin to Tackle Cancer Using Uproleselan.
Muz B, Abdelghafer A, Markovic M, Yavner J, Melam A, Salama NN, Azab AK.
Cancers (Basel). 2021 Jan 18;13(2):335. doi: 10.3390/cancers13020335.
PMID: 33477563 Free PMC article. Review.
3- Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma.
Federico C, Alhallak K, Sun J, Duncan K, Azab F, Sudlow GP, de la Puente P, Muz B, Kapoor V, Zhang L, Yuan F, Markovic M, Kotsybar J, Wasden K, Guenthner N, Gurley S, King J, Kohnen D, Salama NN, Thotala D, Hallahan DE, Vij R, DiPersio JF, Achilefu S, Azab AK.
Nat Commun. 2020 Nov 27;11(1):6037. doi: 10.1038/s41467-020-19932-1.
PMID: 33247158 Free PMC article.
4- Targeting CD47 as a Novel Immunotherapy for Multiple Myeloma.
Sun J, Muz B, Alhallak K, Markovic M, Gurley S, Wang Z, Guenthner N, Wasden K, Fiala M, King J, Kohnen D, Salama NN, Vij R, Azab AK.
Cancers (Basel). 2020 Jan 28;12(2):305. doi: 10.3390/cancers12020305.
PMID: 32012878 Free PMC article.
5- Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial.
Adkins D, Ley J, Neupane P, Worden F, Sacco AG, Palka K, Grilley-Olson JE, Maggiore R, Salama NN, Trinkaus K, Van Tine BA, Steuer CE, Saba NF, Oppelt P.
Lancet Oncol. 2019 Sep;20(9):1295-1305. doi: 10.1016/S1470-2045(19)30405-X. Epub 2019 Jul 24.
PMID: 31351869 Clinical Trial.
6- Single dose oral ranolazine pharmacokinetics in patients receiving maintenance hemodialysis.
Scoville BA, Segal JH, Salama NN, Heung M, Bleske BE, Eyler RF, Mueller BA.
Ren Fail. 2019 Nov;41(1):118-125. doi: 10.1080/0886022X.2019.1585371.
PMID: 30909832 Free PMC article. Clinical Trial.
7- Pazopanib plus cetuximab in recurrent or metastatic head and neck squamous cell carcinoma: an open-label, phase 1b and expansion study.
Adkins D, Mehan P, Ley J, Siegel MJ, Siegel BA, Dehdashti F, Jiang X, Salama NN, Trinkaus K, Oppelt P.
Lancet Oncol. 2018 Aug;19(8):1082-1093. doi: 10.1016/S1470-2045(18)30350-4. Epub 2018 Jul 11.
PMID: 30001987 Free PMC article.
8- Enhancing proteasome-inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma.
de la Puente P, Luderer MJ, Federico C, Jin A, Gilson RC, Egbulefu C, Alhallak K, Shah S, Muz B, Sun J, King J, Kohnen D, Salama NN, Achilefu S, Vij R, Azab AK.
J Control Release. 2018 Jan 28;270:158-176. doi: 10.1016/j.jconrel.2017.11.045. Epub 2017 Nov 28.
PMID: 29196043